Drug profile · INN
bupivacaine hydrochloride
BUPIVACAINE HYDROCHLORIDE
bupivacaine hydrochloride (BUPIVACAINE HYDROCHLORIDE) is a sodium channel protein type iv alpha subunit blocker. Associated with Amphastar France Pharmaceuticals. Route of administration: spinal. Current US regulatory status: approved.
Drug details — bupivacaine hydrochloride
- US status
- approved
- Class
- —
- Route
- SPINAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
bupivacaine hydrochloride (BUPIVACAINE HYDROCHLORIDE) is a sodium channel protein type iv alpha subunit blocker. Associated with Amphastar France Pharmaceuticals. Route of administration: spinal. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel protein type IV alpha subunit blocker
Primary target: Sodium channel protein type 4 subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bupivacaine hydrochloride?
bupivacaine hydrochloride (BUPIVACAINE HYDROCHLORIDE) is a sodium channel protein type iv alpha subunit blocker. Associated with Amphastar France Pharmaceuticals. Route of administration: spinal. Current US regulatory status: approved.
What is the brand name for bupivacaine hydrochloride?
BUPIVACAINE HYDROCHLORIDE is a marketed brand name for bupivacaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bupivacaine hydrochloride?
bupivacaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.